Carbon ion radiation therapy in prostate cancer: The importance of dosage

Teeradon Treechairusame; Pahnwat T Taweesedt

doi:10.4329/wjr.v16.i11.696

Carbon ion radiation therapy in prostate cancer: The importance of dosage

World J Radiol. 2024 Nov 28;16(11):696-699. doi: 10.4329/wjr.v16.i11.696.

Authors

Teeradon Treechairusame¹, Pahnwat T Taweesedt^{2

3}

Affiliations

¹ Division of Radiation Oncology, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
² Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA 94305, United States.
³ Sierra Pacific Mental Illness Research, Education, and Clinical Center, VA Palo Alto Health Care System, Palo Alto, CA 94304, United States. pahnwatt@stanford.edu.

Abstract

In this article, we comment on the article by Ono et al. We focus specifically on the carbon ion radiotherapy studies and the method to calculate the dosing schedule. While photon hypofractionated radiotherapy in prostate cancer has demonstrated improvement in tumor control with reduced gastrointestinal toxicity compared to conventional radiotherapy, carbon ion radiotherapy (CIRT) offers additional physical and biological advantages. Recent findings, including those from Ono et al, have established new dose constraints of CIRT for prostate cancer treatment and risk factors for rectal bleeding. Due to limited data on CIRT dosing, this study underscores the need for more research to refine dose calculation methods and better understand their effects on clinical outcomes.

Keywords: Bleeding; Carbon ion radiotherapy; Dose; Prostate cancer; Toxicity.